(Use of colored or fluorescent dye solutions)
[Package Design & Selection] ➔ [Maximum Allowable Leakage Limit (MALL) Definition] ➔ [Method Validation] ➔ [Routine Manufacturing Controls]
PDA stands for Parenteral Drug Association, a global organization that provides guidance and resources for the pharmaceutical industry. Technical Report 27, in particular, appears to be a document related to the validation of sterile compounding facilities.
This term is used generically to cover all types of physical seals, heat welds, or elastomeric crimping mechanisms.
TR 27 establishes that a leak is an unintended pathway in a container closure system that allows the escape of product or the entry of environmental gases, liquids, or microorganisms. The report explores how the geometry of a leak (tortuosity, path length, and diameter) influences the rate of mass transfer. 2. Microbial Ingress vs. Physical Leaks pda technical report 27 pdf
While PDA TR 27 laid the groundwork, the industry has shifted toward the standards found in . Modern manufacturers now prefer deterministic methods (like Laser-Based Headspace Analysis or High Voltage Leak Detection) over the older probabilistic methods (like Dye Ingress) mentioned in early technical reports.
To address this, the PDA released (often referred to as the revised TR 27).
A critical aspect of the report is its discussion on defining acceptable leak rates. A leak is essentially an unintended opening in a package. The report provides guidance on correlating leak size with potential risks, such as microbial ingress or loss of sterility, helping manufacturers set scientifically justified specifications.
Disclaimer: This write-up is for informational purposes and does not replace the official PDA TR 27 document. Always refer to the current version of the technical report for regulatory and technical compliance. (Use of colored or fluorescent dye solutions) [Package
Still, TR 27 provides the statistical validation framework that these newer methods rely upon.
The latest PDA TR 27 (typically referred to as 2021 revision or current version) incorporates updates for advanced therapies (cell/gene therapies, combination products) and new technologies like laser-drilled hole standards.
You must have an account to complete the purchase. After purchasing, you will receive a for download. If you require multi-user licensing for a team, you should contact PDA directly at info@pda.org.
In the pharmaceutical industry, a "Container Closure System" (CCS) is the sum of packaging components that protect the drug product. If this system fails (e.g., a crack in a vial, a loose syringe plunger, or a faulty blister pack), the product is at risk of contamination, sterility loss, or degradation. TR 27 outlines the lifecycle approach to ensuring these systems remain integral from manufacturing through the product’s shelf life. TR 27 establishes that a leak is an
Historically, the industry relied heavily on , such as the Blue Dye Immersion test or Microbial Challenge test. These tests are:
The document bridges a critical gap: it helps manufacturers translate theoretical leak detection science into practical, defensible quality control procedures.
Detailing the relationship between leak size, gas transport, and microbial ingress.
Acquiring and referencing the PDA TR 27 guideline helps manufacturers align with strict demands from global regulatory bodies like the FDA and EMA.
Historically, a leak diameter of approximately 0.1 to 0.3 micrometers was viewed as the threshold for microbial ingress under specific capillary conditions.